Loading…
Does surgical technique influence outcomes after simultaneous kidney–pancreas transplantation?
Since 1995, many centers have switched from bladder to enteric drainage of the exocrine secretions in simultaneous kidney–pancreas transplantation (SKPT). Enteric exocrine drainage may be performed with either systemic (systemic-enteric [S-E]) or portal (portal-enteric [P-E]) venous delivery of insu...
Saved in:
Published in: | Transplantation proceedings 2004-05, Vol.36 (4), p.1076-1077 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c406t-66727c24793fdaa06206667cabac3a170330516f8bd95bceba46ed16ed3c5d123 |
---|---|
cites | cdi_FETCH-LOGICAL-c406t-66727c24793fdaa06206667cabac3a170330516f8bd95bceba46ed16ed3c5d123 |
container_end_page | 1077 |
container_issue | 4 |
container_start_page | 1076 |
container_title | Transplantation proceedings |
container_volume | 36 |
creator | Stratta, R.J Alloway, R.R Lo, A Hodge, E.E |
description | Since 1995, many centers have switched from bladder to enteric drainage of the exocrine secretions in simultaneous kidney–pancreas transplantation (SKPT). Enteric exocrine drainage may be performed with either systemic (systemic-enteric [S-E]) or portal (portal-enteric [P-E]) venous delivery of insulin. Controversy exists regarding the optimal surgical technique. From March 1999 to May 2001, a total of 297 SKPT patients were enrolled into a prospective, multicenter, randomized, open-label, comparative trial of two daclizumab dosing strategies versus no-antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids in SKPT recipients. Surgical techniques were center specific. A total of 171 patients (58%) underwent SKPT with S-E drainage, 96 (32%) with P-E drainage, and 30 (10%) with systemic-bladder (S-B) drainage. The two groups randomized to daclizumab induction were similar with regard to surgical technique (64% S-E, 25% P-E, 11% S-B drainage). Demographic and transplant characteristics and immunosuppression were similar among the three groups, except that more patients with P-E drainage did not receive antibody induction. At 6 months, no differences were seen in patient and graft survival rates, surgical complications including pancreas thrombosis, rates of rejection or infection, readmissions, and kidney and pancreas allograft function among the three different surgical techniques. The 6-month results of this multicenter study suggest no significant differences in outcomes in SKPT recipients according to surgical technique. |
doi_str_mv | 10.1016/j.transproceed.2004.04.051 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72016865</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0041134504004841</els_id><sourcerecordid>72016865</sourcerecordid><originalsourceid>FETCH-LOGICAL-c406t-66727c24793fdaa06206667cabac3a170330516f8bd95bceba46ed16ed3c5d123</originalsourceid><addsrcrecordid>eNqNkM1u1DAQgC0EotvCK6AICW5Z_JM4u1xQ1ZYfqRIXOJvJZAJeEmexHaTeeAfekCdhoqxQj0hjWfZ8Mx5_QjxXcquksq8O2xwhpGOckKjbaimr7RK1eiA2ateYUlttHooNJ1SpTFWfifOUDpLPujKPxZmq1b4yjdmIL9cTpSLN8atHGIpM-C34HzMVPvTDTAGpmOaM08gU9Jlikfw4DxkCTXMqvvsu0N2fX7-PEDASpGIdbYCQIfspvHkiHvUwJHp62i_E57c3n67el7cf3324urwtsZI2l9Y2ukFdNXvTdwDSamn5DqEFNKAaaQz_z_a7ttvXLVILlaVO8TJYd0qbC_Fy7ctaeP6U3egT0jCsk7pGs7qdrRl8vYIYp5Qi9e4Y_QjxzinpFr_u4O77dYtft0StuPjZ6ZW5HTn3r_QklIEXJwASC-25Efp0j9s10u4lc9crR-zkp6foEvpFd-cjYXbd5P9nnr8CHaO8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72016865</pqid></control><display><type>article</type><title>Does surgical technique influence outcomes after simultaneous kidney–pancreas transplantation?</title><source>Elsevier</source><creator>Stratta, R.J ; Alloway, R.R ; Lo, A ; Hodge, E.E</creator><creatorcontrib>Stratta, R.J ; Alloway, R.R ; Lo, A ; Hodge, E.E ; for the PIVOT Study Group ; PIVOT Study Group</creatorcontrib><description>Since 1995, many centers have switched from bladder to enteric drainage of the exocrine secretions in simultaneous kidney–pancreas transplantation (SKPT). Enteric exocrine drainage may be performed with either systemic (systemic-enteric [S-E]) or portal (portal-enteric [P-E]) venous delivery of insulin. Controversy exists regarding the optimal surgical technique. From March 1999 to May 2001, a total of 297 SKPT patients were enrolled into a prospective, multicenter, randomized, open-label, comparative trial of two daclizumab dosing strategies versus no-antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids in SKPT recipients. Surgical techniques were center specific. A total of 171 patients (58%) underwent SKPT with S-E drainage, 96 (32%) with P-E drainage, and 30 (10%) with systemic-bladder (S-B) drainage. The two groups randomized to daclizumab induction were similar with regard to surgical technique (64% S-E, 25% P-E, 11% S-B drainage). Demographic and transplant characteristics and immunosuppression were similar among the three groups, except that more patients with P-E drainage did not receive antibody induction. At 6 months, no differences were seen in patient and graft survival rates, surgical complications including pancreas thrombosis, rates of rejection or infection, readmissions, and kidney and pancreas allograft function among the three different surgical techniques. The 6-month results of this multicenter study suggest no significant differences in outcomes in SKPT recipients according to surgical technique.</description><identifier>ISSN: 0041-1345</identifier><identifier>EISSN: 1873-2623</identifier><identifier>DOI: 10.1016/j.transproceed.2004.04.051</identifier><identifier>PMID: 15194373</identifier><identifier>CODEN: TRPPA8</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Antibodies, Monoclonal - therapeutic use ; Antibodies, Monoclonal, Humanized ; Biological and medical sciences ; Graft Rejection - epidemiology ; Graft Survival ; Humans ; Immunoglobulin G - therapeutic use ; Immunosuppressive Agents - therapeutic use ; Kidney Function Tests ; Kidney Transplantation - immunology ; Kidney Transplantation - methods ; Kidney Transplantation - mortality ; Medical sciences ; Mycophenolic Acid - analogs & derivatives ; Mycophenolic Acid - therapeutic use ; Pancreas Transplantation - immunology ; Pancreas Transplantation - methods ; Pancreas Transplantation - mortality ; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases ; Surgery of the urinary system ; Survival Analysis ; Survivors ; Tacrolimus - therapeutic use ; Treatment Outcome</subject><ispartof>Transplantation proceedings, 2004-05, Vol.36 (4), p.1076-1077</ispartof><rights>2004 Elsevier Inc.</rights><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c406t-66727c24793fdaa06206667cabac3a170330516f8bd95bceba46ed16ed3c5d123</citedby><cites>FETCH-LOGICAL-c406t-66727c24793fdaa06206667cabac3a170330516f8bd95bceba46ed16ed3c5d123</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,780,784,789,790,23930,23931,25140,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15870690$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15194373$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stratta, R.J</creatorcontrib><creatorcontrib>Alloway, R.R</creatorcontrib><creatorcontrib>Lo, A</creatorcontrib><creatorcontrib>Hodge, E.E</creatorcontrib><creatorcontrib>for the PIVOT Study Group</creatorcontrib><creatorcontrib>PIVOT Study Group</creatorcontrib><title>Does surgical technique influence outcomes after simultaneous kidney–pancreas transplantation?</title><title>Transplantation proceedings</title><addtitle>Transplant Proc</addtitle><description>Since 1995, many centers have switched from bladder to enteric drainage of the exocrine secretions in simultaneous kidney–pancreas transplantation (SKPT). Enteric exocrine drainage may be performed with either systemic (systemic-enteric [S-E]) or portal (portal-enteric [P-E]) venous delivery of insulin. Controversy exists regarding the optimal surgical technique. From March 1999 to May 2001, a total of 297 SKPT patients were enrolled into a prospective, multicenter, randomized, open-label, comparative trial of two daclizumab dosing strategies versus no-antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids in SKPT recipients. Surgical techniques were center specific. A total of 171 patients (58%) underwent SKPT with S-E drainage, 96 (32%) with P-E drainage, and 30 (10%) with systemic-bladder (S-B) drainage. The two groups randomized to daclizumab induction were similar with regard to surgical technique (64% S-E, 25% P-E, 11% S-B drainage). Demographic and transplant characteristics and immunosuppression were similar among the three groups, except that more patients with P-E drainage did not receive antibody induction. At 6 months, no differences were seen in patient and graft survival rates, surgical complications including pancreas thrombosis, rates of rejection or infection, readmissions, and kidney and pancreas allograft function among the three different surgical techniques. The 6-month results of this multicenter study suggest no significant differences in outcomes in SKPT recipients according to surgical technique.</description><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Biological and medical sciences</subject><subject>Graft Rejection - epidemiology</subject><subject>Graft Survival</subject><subject>Humans</subject><subject>Immunoglobulin G - therapeutic use</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Kidney Function Tests</subject><subject>Kidney Transplantation - immunology</subject><subject>Kidney Transplantation - methods</subject><subject>Kidney Transplantation - mortality</subject><subject>Medical sciences</subject><subject>Mycophenolic Acid - analogs & derivatives</subject><subject>Mycophenolic Acid - therapeutic use</subject><subject>Pancreas Transplantation - immunology</subject><subject>Pancreas Transplantation - methods</subject><subject>Pancreas Transplantation - mortality</subject><subject>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</subject><subject>Surgery of the urinary system</subject><subject>Survival Analysis</subject><subject>Survivors</subject><subject>Tacrolimus - therapeutic use</subject><subject>Treatment Outcome</subject><issn>0041-1345</issn><issn>1873-2623</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><recordid>eNqNkM1u1DAQgC0EotvCK6AICW5Z_JM4u1xQ1ZYfqRIXOJvJZAJeEmexHaTeeAfekCdhoqxQj0hjWfZ8Mx5_QjxXcquksq8O2xwhpGOckKjbaimr7RK1eiA2ateYUlttHooNJ1SpTFWfifOUDpLPujKPxZmq1b4yjdmIL9cTpSLN8atHGIpM-C34HzMVPvTDTAGpmOaM08gU9Jlikfw4DxkCTXMqvvsu0N2fX7-PEDASpGIdbYCQIfspvHkiHvUwJHp62i_E57c3n67el7cf3324urwtsZI2l9Y2ukFdNXvTdwDSamn5DqEFNKAaaQz_z_a7ttvXLVILlaVO8TJYd0qbC_Fy7ctaeP6U3egT0jCsk7pGs7qdrRl8vYIYp5Qi9e4Y_QjxzinpFr_u4O77dYtft0StuPjZ6ZW5HTn3r_QklIEXJwASC-25Efp0j9s10u4lc9crR-zkp6foEvpFd-cjYXbd5P9nnr8CHaO8</recordid><startdate>20040501</startdate><enddate>20040501</enddate><creator>Stratta, R.J</creator><creator>Alloway, R.R</creator><creator>Lo, A</creator><creator>Hodge, E.E</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20040501</creationdate><title>Does surgical technique influence outcomes after simultaneous kidney–pancreas transplantation?</title><author>Stratta, R.J ; Alloway, R.R ; Lo, A ; Hodge, E.E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c406t-66727c24793fdaa06206667cabac3a170330516f8bd95bceba46ed16ed3c5d123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Biological and medical sciences</topic><topic>Graft Rejection - epidemiology</topic><topic>Graft Survival</topic><topic>Humans</topic><topic>Immunoglobulin G - therapeutic use</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Kidney Function Tests</topic><topic>Kidney Transplantation - immunology</topic><topic>Kidney Transplantation - methods</topic><topic>Kidney Transplantation - mortality</topic><topic>Medical sciences</topic><topic>Mycophenolic Acid - analogs & derivatives</topic><topic>Mycophenolic Acid - therapeutic use</topic><topic>Pancreas Transplantation - immunology</topic><topic>Pancreas Transplantation - methods</topic><topic>Pancreas Transplantation - mortality</topic><topic>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</topic><topic>Surgery of the urinary system</topic><topic>Survival Analysis</topic><topic>Survivors</topic><topic>Tacrolimus - therapeutic use</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stratta, R.J</creatorcontrib><creatorcontrib>Alloway, R.R</creatorcontrib><creatorcontrib>Lo, A</creatorcontrib><creatorcontrib>Hodge, E.E</creatorcontrib><creatorcontrib>for the PIVOT Study Group</creatorcontrib><creatorcontrib>PIVOT Study Group</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Transplantation proceedings</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stratta, R.J</au><au>Alloway, R.R</au><au>Lo, A</au><au>Hodge, E.E</au><aucorp>for the PIVOT Study Group</aucorp><aucorp>PIVOT Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Does surgical technique influence outcomes after simultaneous kidney–pancreas transplantation?</atitle><jtitle>Transplantation proceedings</jtitle><addtitle>Transplant Proc</addtitle><date>2004-05-01</date><risdate>2004</risdate><volume>36</volume><issue>4</issue><spage>1076</spage><epage>1077</epage><pages>1076-1077</pages><issn>0041-1345</issn><eissn>1873-2623</eissn><coden>TRPPA8</coden><abstract>Since 1995, many centers have switched from bladder to enteric drainage of the exocrine secretions in simultaneous kidney–pancreas transplantation (SKPT). Enteric exocrine drainage may be performed with either systemic (systemic-enteric [S-E]) or portal (portal-enteric [P-E]) venous delivery of insulin. Controversy exists regarding the optimal surgical technique. From March 1999 to May 2001, a total of 297 SKPT patients were enrolled into a prospective, multicenter, randomized, open-label, comparative trial of two daclizumab dosing strategies versus no-antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids in SKPT recipients. Surgical techniques were center specific. A total of 171 patients (58%) underwent SKPT with S-E drainage, 96 (32%) with P-E drainage, and 30 (10%) with systemic-bladder (S-B) drainage. The two groups randomized to daclizumab induction were similar with regard to surgical technique (64% S-E, 25% P-E, 11% S-B drainage). Demographic and transplant characteristics and immunosuppression were similar among the three groups, except that more patients with P-E drainage did not receive antibody induction. At 6 months, no differences were seen in patient and graft survival rates, surgical complications including pancreas thrombosis, rates of rejection or infection, readmissions, and kidney and pancreas allograft function among the three different surgical techniques. The 6-month results of this multicenter study suggest no significant differences in outcomes in SKPT recipients according to surgical technique.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>15194373</pmid><doi>10.1016/j.transproceed.2004.04.051</doi><tpages>2</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0041-1345 |
ispartof | Transplantation proceedings, 2004-05, Vol.36 (4), p.1076-1077 |
issn | 0041-1345 1873-2623 |
language | eng |
recordid | cdi_proquest_miscellaneous_72016865 |
source | Elsevier |
subjects | Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Biological and medical sciences Graft Rejection - epidemiology Graft Survival Humans Immunoglobulin G - therapeutic use Immunosuppressive Agents - therapeutic use Kidney Function Tests Kidney Transplantation - immunology Kidney Transplantation - methods Kidney Transplantation - mortality Medical sciences Mycophenolic Acid - analogs & derivatives Mycophenolic Acid - therapeutic use Pancreas Transplantation - immunology Pancreas Transplantation - methods Pancreas Transplantation - mortality Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases Surgery of the urinary system Survival Analysis Survivors Tacrolimus - therapeutic use Treatment Outcome |
title | Does surgical technique influence outcomes after simultaneous kidney–pancreas transplantation? |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T06%3A18%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Does%20surgical%20technique%20influence%20outcomes%20after%20simultaneous%20kidney%E2%80%93pancreas%20transplantation?&rft.jtitle=Transplantation%20proceedings&rft.au=Stratta,%20R.J&rft.aucorp=for%20the%20PIVOT%20Study%20Group&rft.date=2004-05-01&rft.volume=36&rft.issue=4&rft.spage=1076&rft.epage=1077&rft.pages=1076-1077&rft.issn=0041-1345&rft.eissn=1873-2623&rft.coden=TRPPA8&rft_id=info:doi/10.1016/j.transproceed.2004.04.051&rft_dat=%3Cproquest_cross%3E72016865%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c406t-66727c24793fdaa06206667cabac3a170330516f8bd95bceba46ed16ed3c5d123%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=72016865&rft_id=info:pmid/15194373&rfr_iscdi=true |